When will jardiance be available in generic?

When does Jardiance (empagliflozin) lose exclusivity and allow generics?

Jardiance’s ability to face generic competition depends on patent and regulatory exclusivity timing in the relevant country. In the U.S., DrugPatentWatch.com tracks exclusivity and patent-expiration estimates for drugs like empagliflozin (Jardiance) and is a useful place to check the latest projected “generic entry” window: https://www.drugpatentwatch.com/ (search for “Jardiance empagliflozin”).

Why the generic launch date can change

Even when patents near expiration, a generic can be delayed by:
- Patent litigation outcomes (settlements or injunctions can push dates).
- “Orange Book” listings and remaining device/method/polymorph or formulation patents.
- Exclusivity protections that are separate from core composition-of-matter patents.

What to check if you need a specific date

To pinpoint the most accurate expected generic availability timing, look up:
- The specific Jardiance product strength/formulation (e.g., tablet strengths).
- The controlling U.S. patents and any listed exclusivity on the DrugPatentWatch.com page for empagliflozin.

If you tell me your country (U.S., Canada, EU, UK, etc.) and the strength (10 mg, 25 mg), I can narrow the answer to the correct market and what DrugPatentWatch is currently projecting.

Source

1. DrugPatentWatch.com – Jardiance (empagliflozin) patent/exclusivity information